Sage (SAGE) Q2 Revenue Jumps 264%
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company focused on developing medicines for brain health disorders, released its second quarter 2025 results on July 30, 2025. The most important news from the quarter was the significant revenue beat, as sales reached $31.7 million (GAAP) against analyst estimates of $16.8 million. This growth was fueled by accelerating uptake of ZURZUVAE, an oral therapy for postpartum depression. The company also narrowed its net loss, reporting improved earnings per share (EPS) of $(0.79) (GAAP) for Q2 2025, beating expectations for $(0.94). Overall, the company reported strong commercial momentum for ZURZUVAE, notable cost cuts in research and development (R), and continued investment in its commercial launch, while ongoing expenses and a reliance on a single product remain points of scrutiny.
Source: Analyst estimates for the quarter provided by FactSet.
Sage Therapeutics develops medicines for disorders affecting the central nervous system with a focus on brain health conditions, such as depression and neurodevelopmental disorders. Its business centers around getting new treatments to market and expanding the clinical pipeline beyond the initial offering.
Source Fool.com
